Current Report Filing (8-k)
23 February 2019 - 12:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2019
Heron Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33221
|
|
94-2875566
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
4242 Campus Point Court, Suite 200, San Diego, CA
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (858)
251-4400
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02
|
Results of Operations and Financial Condition.
|
On February 22, 2019, Heron Therapeutics, Inc. (Company) issued a press release announcing its financial results for the three and twelve
months ended December 31, 2018 (Earnings Press Release). A copy of the Earnings Press Release is furnished as Exhibit 99.1.
This Item
2.02 and the Earnings Press Release attached hereto as Exhibit 99.1, insofar as they disclose information regarding the Companys results of operations or financial condition for the three and twelve months ended December 31, 2018, are
being furnished to the Securities and Exchange Commission.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Heron Therapeutics, Inc.
|
|
|
|
|
Date: February 22, 2019
|
|
|
|
|
|
/s/ Robert E. Hoffman
|
|
|
|
|
|
|
Robert E. Hoffman
Chief Financial
Officer & Senior Vice President, Finance
|
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart
From May 2023 to May 2024